Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses
Open Access
- 10 May 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 6 (1), 1-4
- https://doi.org/10.1038/s41392-021-00608-1
Abstract
No abstract availableKeywords
Funding Information
- Division of Cancer Prevention, National Cancer Institute (R01CA244825)
This publication has 5 references indexed in Scilit:
- AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cellsCell Research, 2021
- ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbiditieseLife, 2020
- MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2020
- ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19The Journal of Infectious Diseases, 2020
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDSNature, 2015